Metastatic Prostate Cancer Clinical Trials

26 studies are recruiting for metastatic prostate cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

   This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnosis (de novo low vol…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07650240 on ClinicalTrials.gov

2. High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

   This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically un…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado

   Locations

   17 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT05011383 on ClinicalTrials.gov

3. Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

   This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Run by

   Janux Therapeutics

   See if you can join NCT07813637 on ClinicalTrials.gov

4. Collection of Blood From Patients With Prostate Cancer

   Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although ever…

   Stage

   Not phased

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00923221 on ClinicalTrials.gov

5. Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

   The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metas…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06040125 on ClinicalTrials.gov

6. First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

   This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further sp…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Research Site, Orlando, Florida

   Locations

   8 in total

   Run by

   AstraZeneca

   See if you can join NCT07529717 on ClinicalTrials.gov

7. A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth, Scottsdale, Arizona

   Locations

   26 in total

   Run by

   Genentech, Inc.

   See if you can join NCT05800665 on ClinicalTrials.gov

8. Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

   The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Arkansas for Medical Sciences, Little Rock, Arkansas

   Run by

   University of Arkansas

   See if you can join NCT07224009 on ClinicalTrials.gov

9. A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

   The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health Research Institute, Scottsdale, Arizona

   Locations

   5 in total

   Run by

   Genentech, Inc.

   See if you can join NCT07567846 on ClinicalTrials.gov

10. Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

    Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Rocky Mountain Cancer Center, Colorado Springs, Colorado

    Locations

    18 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT06800313 on ClinicalTrials.gov

11. A Study of Tarlatamab for People With Prostate Cancer

    The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refrac…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego, California

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07111507 on ClinicalTrials.gov

12. Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

    The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

    Stage

    Phase 1

    Ages

    18 to 130

    Site

    Research Site, Fayetteville, Arkansas

    Locations

    52 in total

    Run by

    AstraZeneca

    See if you can join NCT07181161 on ClinicalTrials.gov

13. Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

    The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    Research Site, South Pasadena, California

    Locations

    37 in total

    Run by

    AstraZeneca

    See if you can join NCT07590934 on ClinicalTrials.gov

14. Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

    The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

    Stage

    Phase 2

    Ages

    19 and older

    Site

    Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT06738303 on ClinicalTrials.gov

15. Study of ORIC-944 in Patients With Metastatic Prostate Cancer

    The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Rocky Mountain Cancer Center, Colorado Springs, Colorado

    Locations

    27 in total

    Run by

    ORIC Pharmaceuticals

    See if you can join NCT05413421 on ClinicalTrials.gov

16. Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

    The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigu…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Huntsman Cancer Institute, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT06112990 on ClinicalTrials.gov

17. 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

    This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastase…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT07145177 on ClinicalTrials.gov

18. Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

    This study consists of two home-based exercise programs: a stationary exercise bicycle intervention (Arm A), and a walking intervention (Arm B). The study will enroll 24 patients who are starting ADT (Androgen Deprivation Therapy)/ARSI (Androgen-Receptor Signaling Inhibitors) therapy for newly diag…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    Paul Viscuse

    See if you can join NCT06429813 on ClinicalTrials.gov

19. Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

    This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic pros…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California

    Locations

    20 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT04787744 on ClinicalTrials.gov

20. Study of AZD0754 in Participants With Metastatic Prostate Cancer

    The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

    Stage

    Phase 1

    Ages

    18 to 130

    Site

    Research Site, Duarte, California

    Locations

    15 in total

    Run by

    AstraZeneca

    See if you can join NCT06267729 on ClinicalTrials.gov

21. Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

    To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06616597 on ClinicalTrials.gov

22. Physician- and Patient-based Barriers to NGS Testing

    The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT07209176 on ClinicalTrials.gov

23. Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

    This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06062745 on ClinicalTrials.gov

24. Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer

    People with prostate cancer may have a decreased quality of life due to the cancer itself and due to a lifesaving cancer treatment. Physical therapy, including regular exercise, helps patients with cancer to reduce disease symptoms and improve their quality of life. However, cancer rehabilitation p…

    Stage

    Not phased

    Ages

    21 and older

    Site

    University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT07032584 on ClinicalTrials.gov

25. A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

    The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma vir…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    ImmunoGenesis

    See if you can join NCT06782555 on ClinicalTrials.gov